Zhonghui Biotech : Conclut un accord de coopération stratégique pour le développement du marché international du vaccin antigrippal avec Watson Biotech Hong Kong

Zhonghui Biotech Announcement, the company has entered into a strategic cooperation agreement with Watson Biotech Hong Kong Limited regarding the overseas expansion of subunit influenza vaccines. According to the strategic cooperation agreement, both parties will conduct in-depth cooperation on the registration, sales, and commercialization of the group’s R&D products in overseas markets. The core product for this overseas expansion is the group’s self-developed trivalent subunit influenza vaccine (Hui’er Kangxin 3). This product was approved for listing in January 2026 and is China’s first and only trivalent subunit influenza vaccine suitable for the entire population aged 6 months and above.